title: Using multivalent adenoviral vectors for HIV vaccination.
abstract: Adenoviral vectors have been used for a variety of vaccine applications including cancer and infectious diseases. Traditionally, Ad-based vaccines are designed to express antigens through transgene expression of a given antigen. For effective vaccine development it is often necessary to express or present multiple antigens to the immune system to elicit an optimal vaccine as observed preclinically with mosaic/polyvalent HIV vaccines or malaria vaccines. Due to the wide flexibility of Ad vectors they are an ideal platform for expressing large amounts of antigen and/or polyvalent mosaic antigens. Ad vectors that display antigens on their capsid surface can elicit a robust humoral immune response, the "antigen capsid-incorporation" strategy. The adenoviral hexon protein has been utilized to display peptides in the majority of vaccine strategies involving capsid incorporation. Based on our abilities to manipulate hexon HVR2 and HVR5, we sought to manipulate HVR1 in the context of HIV antigen display for the first time ever. More importantly, peptide incorporation within HVR1 was utilized in combination with other HVRs, thus creating multivalent vectors. To date this is the first report where dual antigens are displayed within one Ad hexon particle. These vectors utilize HVR1 as an incorporation site for a seven amino acid region of the HIV glycoprotein 41, in combination with six Histidine incorporation within HVR2 or HVR5. Our study illustrates that these multivalent antigen vectors are viable and can present HIV antigen as well as His6 within one Ad virion particle. Furthermore, mouse immunizations with these vectors demonstrate that these vectors can elicit a HIV and His6 epitope-specific humoral immune response.
authors.affiliation: Department of Medicine, Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham, Alabama, United States of America.
authors.forename: Linlin
authors.initials: L
authors.lastname: Gu
authors.forename: Zan C
authors.initials: ZC
authors.lastname: Li
authors.forename: Alexandre
authors.initials: A
authors.lastname: Krendelchtchikov
authors.forename: Valentina
authors.initials: V
authors.lastname: Krendelchtchikova
authors.forename: Hongju
authors.initials: H
authors.lastname: Wu
authors.forename: Qiana L
authors.initials: QL
authors.lastname: Matthews
mesh_terms: D016915:AIDS Vaccines / Q000235:genetics* / Q000276:immunology / Q000627:therapeutic use; D000256:Adenoviridae / Q000235:genetics*; D000818:Animals; D000917:Antibody Formation; D005260:Female; D005822:Genetic Vectors / Q000235:genetics* / Q000276:immunology / Q000627:therapeutic use; D057809:HEK293 Cells; D006678:HIV / Q000235:genetics* / Q000276:immunology; D015488:HIV Antigens / Q000235:genetics* / Q000276:immunology / Q000627:therapeutic use; D015658:HIV Infections / Q000517:prevention & control*; D006639:Histidine / Q000235:genetics / Q000276:immunology / Q000627:therapeutic use; D006801:Humans; D056724:Immunity, Humoral; D007114:Immunization; D051379:Mice; D008807:Mice, Inbred BALB C; D009842:Oligopeptides / Q000235:genetics / Q000276:immunology / Q000627:therapeutic use
chemical_list: D016915:AIDS Vaccines; D015488:HIV Antigens; C471213:His-His-His-His-His-His; D009842:Oligopeptides; D006639:Histidine
references.citation: J Virol. 2010 Feb;84(4):1967-76
references.pmid: 20007267
references.citation: PLoS One. 2010 Jul 27;5(7):e11815
references.pmid: 20676400
references.citation: J Clin Invest. 2010 Oct;120(10):3688-701
references.pmid: 20811151
references.citation: Vaccine. 2012 Jan 11;30(3):506-9
references.pmid: 22133509
references.citation: Mol Pharm. 2011 Feb 7;8(1):3-11
references.pmid: 21047139
references.citation: J Virol. 2006 Jun;80(11):5361-70
references.pmid: 16699016
references.citation: J Gen Virol. 1994 Jan;75 ( Pt 1):133-9
references.pmid: 7509367
references.citation: J Virol. 1993 Nov;67(11):6642-7
references.pmid: 7692082
references.citation: Blood. 2010 Sep 9;116(10):1669-77
references.pmid: 20511542
references.citation: J Virol. 2005 Jan;79(2):1252-61
references.pmid: 15613352
references.citation: Curr Opin Infect Dis. 2003 Apr;16(2):135-43
references.pmid: 12734446
references.citation: J Virol. 2009 Mar;83(5):2201-15
references.pmid: 19109395
references.citation: AIDS Res Hum Retroviruses. 2001 Dec 10;17(18):1757-65
references.pmid: 11788027
references.citation: J Clin Invest. 2005 May;115(5):1281-9
references.pmid: 15841217
references.citation: J Virol. 2005 Mar;79(6):3382-90
references.pmid: 15731232
references.citation: J Virol. 2001 Nov;75(22):10892-905
references.pmid: 11602729
references.citation: J Virol. 2002 Dec;76(24):12775-82
references.pmid: 12438602
references.citation: Virol J. 2008 Aug 21;5:98
references.pmid: 18718011
references.citation: AIDS. 1996 Jun;10(6):587-93
references.pmid: 8780812
references.citation: Vaccine. 2011 Feb 11;29(8):1683-9
references.pmid: 21199707
references.citation: PLoS One. 2010 Sep 21;5(9):e12873
references.pmid: 20877623
references.citation: J Gene Med. 2009 Jul;11(7):570-9
references.pmid: 19391169
references.citation: Nat Med. 2010 Mar;16(3):319-23
references.pmid: 20173752
references.citation: J Innate Immun. 2010;2(4):353-9
references.pmid: 20375551
references.citation: Nat Med. 2007 Jan;13(1):100-6
references.pmid: 17187074
references.citation: AIDS Res Hum Retroviruses. 1994 Dec;10(12):1651-8
references.pmid: 7888224
references.citation: J Virol. 2004 Mar;78(5):2572-80
references.pmid: 14963160
references.citation: AIDS Res Hum Retroviruses. 1994 Apr;10(4):359-69
references.pmid: 7520721
references.citation: J Virol. 2007 Dec;81(24):13801-8
references.pmid: 17942539
references.citation: Arch Virol. 2012 Sep;157(9):1709-18
references.pmid: 22669318
references.citation: J Virol. 1999 Jun;73(6):5156-61
references.pmid: 10233980
references.citation: J Virol. 2006 Jun;80(11):5523-30
references.pmid: 16699033
references.citation: Virology. 2008 Aug 1;377(2):391-400
references.pmid: 18570971